Results 61 to 70 of about 659,276 (230)

Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: Role of GLP-1 isoforms in Glut4 receptor trafficking [PDF]

, 2018
Background: The distribution of glucose and fatty-acid transporters in the heart is crucial for energy consecution and myocardial function. In this sense, the glucagon-like peptide-1 (GLP-1) enhancer, sitagliptin, improves glucose homeostasis but it ...
Caro-Vadillo, A., Cruz, F., Egido, J., González-Bris, A., Lorenzo, Ó., Morcillo, M. A., Oteo, M., Picatoste, Belén, Ramírez, E., Tuñón, J.   +9 more
core   +2 more sources

Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: Close analogs of JANUVIA™ (sitagliptin phosphate)

Bioorganic & Medicinal Chemistry Letters, 2007
A series of beta-aminoamides bearing triazolopiperazines has been prepared and evaluated as potent, selective, orally active dipeptidyl peptidase IV (DPP-4) inhibitors. Efforts at optimization of the beta-aminoamide series, which ultimately led to the discovery of JANUVIA (sitagliptin phosphate, compound 1), are described.
Dooseop Kim, Jennifer E. Kowalchick, Scott D. Edmondson, Anthony Mastracchio, Jinyou Xu, George J. Eiermann, Barbara Leiting, Joseph K. Wu, KellyAnn D. Pryor, Reshma A. Patel, Huaibing He, Kathryn A. Lyons, Nancy A. Thornberry, Ann E. Weber   +13 more
openalex   +3 more sources

Canagliflozin: A Review in Type 2 Diabetes. [PDF]

, 2017
peer reviewedCanagliflozin (Invokana(R)) is a sodium-glucose co-transporter-2 (SGLT2) inhibitor indicated in various countries worldwide for the once-daily oral treatment of type 2 diabetes (T2D).
Deeks, Emma D., Scheen, André
core   +2 more sources

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes : systematic review and economic evaluation [PDF]

, 2017
Background Most people with type 2 diabetes are overweight, so initial treatment is aimed at reducing weight and increasing physical activity. Even modest weight loss can improve control of blood glucose.
Clar, Christine, Clegg, Andrew, Colquitt, Jill, Court, Rachel A., Cummins, Ewen, Holt, Tim, Johnston, Rhona, McGrane, David, O'Hare, J. Paul, Royle, Pamela, Shantikumar, Saran, Tan, Bee K., Uthman, Olalekan A., Waugh, Norman   +13 more
core   +3 more sources

Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes

Clinics, 2019
OBJECTIVE: To assess the efficacy and safety of sitagliptin compared with voglibose added to combined metformin and insulin in patients with newly diagnosed type 2 diabetes (T2DM).
Chunhong Shi, Ru Zhang, Ran Bai, Dan Liu, Yongbo Wang, Xueyang Zhang, Hao Wang, Jianling Du   +7 more
doaj   +1 more source

Circadian Immunity and Vascular Inflammation in Cardiovascular Disease Chronotherapy Windows: Time for a Re‐Assessment

Med Research, EarlyView.
ABSTRACT Circadian rhythms orchestrate cardiovascular physiology by regulating immune and inflammatory pathways. Disruption of these rhythms profoundly alters vascular homeostasis, thereby promoting the onset and progression of cardiovascular diseases (CVD).
Tian Zhang, Ge Zhang, Tian‐Ding Liu, Tianshu Gu, Fengyi Yu, Pengyuan Xu, Wunan Mi, Xuanjiang Zhao, Qian Guo, Honglin Zheng, Taiqi Zhao, Qiang Li, Di Lu, Mingxuan Duan, Chaoyang Yu, Ruhao Wu, Shiqian Zhang, Haonan Zhang, Zeyu Wang, Youyang Zheng, Yan Xiao, Zenglei Zhang, Ge Zhang   +22 more
wiley   +1 more source

Vildagliptin and Omarigliptin Differentially Bind to DPP‐4 Homodimers and Modulate Osteoclast‐Mediated Bone Resorption

Comprehensive Physiology, Volume 16, Issue 1, February 2026.
Vildagliptin and omarigliptin, dipeptidyl peptidase‐4 (DPP‐4) inhibitors, have differential effects on bone cells. Although vildagliptin improved the bone microstructure of high‐fat diet‐fed rats, it was unable to downregulate osteoclastogenesis or the expression of key osteoclast transcripts.
Ratchaneevan Aeimlapa, Jiraporn Panmanee, Jarinthorn Teerapornpuntakit, Kannikar Wongdee, Jirawan Thongbunchoo, Nattapon Panupinthu, Saovaros Svasti, Nattayaporn Apaijai, Piangkwan Sa‐nguanmoo, Siriporn Chattipakorn, Nipon Chattipakorn, Narattaphol Charoenphandhu   +11 more
wiley   +1 more source

Investigating operational stability and causes of cofactor release in fold type I amine transaminase

Protein Science, Volume 35, Issue 2, February 2026.
Abstract Amine transaminases (ATAs) are pyridoxal phosphate (PLP) dependent biocatalysts frequently employed in chiral amine synthesis. Yields of ATA‐catalyzed reactions often suffer from low enzyme operational stability due to weak interactions between the ATA and the aminated cofactor pyridoxamine phosphate (PMP), which can leak from the active site ...
Xuebin Feng, William Chau, Emma R. Master   +2 more
wiley   +1 more source

Do incretins improve endothelial function? [PDF]

, 2014
An impaired endothelial function has been recognized in the early stage of atherosclerosis, and is a major factor affecting the future development of cardiovascular events.
Jun-ichi Oyama, Koichi Node, Yukihito Higashi   +2 more
core   +1 more source

Lack of Evidence for a Harmful Effect of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Fracture Risk among Type 2 Diabetes Patients: A Network and Cumulative Meta-Analysis of Randomized Controlled Trials [PDF]

, 2016
Aim To evaluate the comparative effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on risk of bone fracture in patients with type 2 diabetes mellitus (T2DM).
Hsu, Y. H., Li, D. D., Song, Y. Q., Tang, H. L., Wang, T. S., Zhai, S. D., Zhang, J. J.   +6 more
core   +2 more sources